It has been suggested that fibrates, lipid-lowering agents with a peroxisome proliferator-activated receptor-a agonistic property, lower blood pressure (BP) in some experimental models of hypertension. However, the effect of fibrates on BP in humans has been inconsistent, and there are few studies using home or ambulatory BP monitoring. We investigated the effects of bezafibrate on office, home and ambulatory BP in hypertensive patients with dyslipidemia. Thirty-two essential hypertensive patients with dyslipidemia (6 men and 26 women, mean age 65 ± 8 years old) were assigned to a control period and a bezafibrate period (200 mg twice daily) for 8 weeks each in a randomized crossover manner. Bezafibrate significantly reduced serum triglyceride, total and lowdensity lipoprotein-cholesterol, blood glucose, plasma insulin, the homeostasis model assessment ratio and increased high-density lipoprotein-cholesterol. Compared with the control period, changes in office, home and 24-h BP with bezafibrate were À 0.7 ± 2.1/ À 1.6 ± 1.2 mm Hg, þ 0.9 ± 1.0/ À 0.5 ± 0.6 and þ 0.8 ± 1.4/ À 0.6 ± 0.9 mm Hg, respectively. None of these differences in BP was significant. In conclusion, bezafibrate improved lipid metabolism and insulin sensitivity but did not affect office, home or ambulatory BP in hypertensive patients with dyslipidemia. Fibrates do not appear to lower BP in patients with essential hypertension.
INTRODUCTION
Hypertension and dyslipidemia are frequently associated and their combination additionally increases cardiovascular risk. [1] [2] [3] Hypertension and dyslipidemia, especially hypertriglyceridemia are also closely linked to obesity, insulin resistance, impaired glucose tolerance and metabolic syndrome. 2, 4, 5 Fibrates have been widely used in the treatment of dyslipidemia. They act as PPAR (peroxisome proliferator-activated receptor)-a agonists, reduce serum triglyceride and LDL (low-density lipoprotein)-cholesterol and increase the level of high-density lipoprotein (HDL)-cholesterol. 6, 7 Fibrates have also been shown to improve insulin sensitivity. [6] [7] [8] It has been suggested that fibrates lower blood pressure (BP) in several experimental models of hypertension. [9] [10] [11] However, results of clinical studies regarding the effect of fibrates on BP were inconsistent, [12] [13] [14] [15] and there are few studies using home or ambulatory BP monitoring in the assessment of changes in BP. It is well documented that home BP and ambulatory BP are superior to office BP in the diagnosis and treatment of hypertension. 16, 17 Home BP measurement and ambulatory BP monitoring can detect small changes in BP caused by pharmacological and non-pharmacological interventions in a limited number of subjects. [18] [19] [20] In the present study, we examined the effects of bezafibrate on office, home and 24-h BP, as well as lipid and glucose metabolism, in hypertensive patients with dyslipidemia.
SUBJECTS AND METHODS
Participants were recruited from the Hypertension Clinic of the National Cerebral and Cardiovascular Center, Osaka, Japan. The study subjects included 32 essential hypertensive patients, 26 women and 6 men, mean age 65±8 years, who had dyslipidemia. Hypertension was considered to be present if the patients showed systolic BP (SBP) X140 mm Hg and/or diastolic BP X90 mm Hg, or if they were on antihypertensive medication. Dyslipidemia was defined as serum total cholesterol X220 mg dl À 1 and/or fasting serum triglyceride X150 mg dl À 1 . This study was performed in accordance with the institutional guideline and approved by the ethical committee. Written informed consent was obtained from each patient.
The subjects were randomly assigned to an 8-week bezafibrate period (200 mg twice a day) and an 8-week control period in a crossover design. Office BP and 24-h ambulatory BP were measured at the end of the control and bezafibrate periods. Home BP was measured throughout the study protocol. At the end of each period, fasting blood samples were obtained to determine lipids, glucose and insulin. The majority of patients (n ¼ 25) were being treated with antihypertensive drugs, but no patients were treated with lipid-lowering agents before this study. Antihypertensive therapy was continued without any alterations throughout the study protocol.
Office BP was measured twice with a mercury sphygmomanometer by a doctor while the patients were quietly seated, and the averaged values were used for analysis. Home BP was measured in the sitting position by the patients three times in the early morning and in the late evening, using semiautomatic devices with the oscillometric method (HEM-757, Omron Corp., Kyoto, Japan). The average values of home BP during the last 7 days of each period (42 records) were used for statistical analysis. Ambulatory BP was monitored oscillometrically every 30 min for 25-26 h using an automatic device (TM-2421; A&D Co. Ltd., Tokyo, Japan). The accuracy and performance of this device have been demonstrated previously. 21 The same recorder was used in each subject to avoid errors due to differences in equipment. After discarding records during the first 1 h, the average values of 24-h records were used for analysis. The homeostasis model assessment ratio (HOMA-R), an index of insulin resistance, was calculated as fasting plasma glucose (mg dl À 1 ) Â fasting insulin (mU ml À 1 )/405. 22 Values are presented as the mean ± s.d. The Student's paired t-test was used to compare the two groups of data. P-values o0.05 were considered statistically significant. Analyses were performed using Stat View software (Abacus Concepts Inc., Berkeley, CA, USA).
RESULTS
Clinical characteristics and biochemical parameters of the subjects in the control and bezafibrate periods are shown in Table 1 . Treatment with bezafibrate significantly reduced levels of serum total cholesterol, triglyceride and LDL-cholesterol, and significantly increased serum HDL-cholesterol (Table 1, Figure 1 ). Bezafibrate also significantly reduced blood glucose, plasma insulin and HOMA-R, but it did not affect serum HbA1c and decreased estimated glomerular filtration rate (Table 1, Figure 2 ).
The levels of office, home and 24-h BP were similar between the bezafibrate and control periods ( Table 2) . Changes in office, home and 24-h BP with bezafibrate were À 0.7±2.1/ À 1.6±1.2 mm Hg, þ 0.9 ± 1.0/ À 0.5 ± 0.6 mm Hg and þ 0.8 ± 1.4/ À 0.6 ± 0.9 mm Hg, respectively. None of these changes was statistically significant.
In univariate analyses, the changes in office, home and 24-h BP with bezafibrate inversely correlated with the baseline levels of each corresponding BP (data not shown). There were no significant relationships between the changes in office, home or 24-h BP with bezafibrate treatment and the changes in lipid and glucose metabolism parameters.
DISCUSSION
In the present study, we demonstrated that administration of bezafibrate for 8 weeks improved lipid metabolism and insulin sensitivity in hypertensive patients with dyslipidemia. However, bezafibrate did not affect any of the office, home or 24-h BP levels in these patients.
Hypertriglyceridemia, part of a complex metabolic disorder, is strongly associated with all atherogenic factors such as disturbances in coagulation and fibrinolysis, the occurrence of hypertension, and the presence of both hyperinsulinemia and elevated free fatty acid levels. 23 Many previous studies have shown that serum triglyceride levels are independently predictive of CVD (cardiovascular disease). [24] [25] [26] A low serum HDL-cholesterol level is associated with a high risk of atherosclerosis. 27 The combination of low HDL-cholesterol and high triglyceride has been shown to be a stronger risk factor for CVD, 3, 28 and to be associated with hyperinsulinemia. 29 Regarding the treatment of dyslipidemia, reducing triglyceride with bezafibrate was suggested to be important for the prevention of CVD. 30 Because bezafibrate has been reported to delay the progression of atherosclerotic lesions, 31 fibrates seem to play a prominent role in the management of dyslipidemia.
In the present study, bezafibrate significantly reduced blood glucose, plasma insulin and HOMA-R, indicating an improvement in insulin resistance. It has been suggested that fibrates not only reduce lipid levels by increasing catabolism of very low-density lipoprotein, 32 but also improve insulin sensitivity and fatty acid composition of skeletal muscle triglycerides by reducing intramuscular lipid content. 33, 34 Fibrates may improve metabolic disorders by regulation of insulin concentration, regulation of plasma and cell membrane lipid composition and activation of PPAR-related genes and proteins in many organs and tissues.
Although dyslipidemia often coexists with hypertension, it has not been recognized as a major determinant of BP. However, there is some evidence suggesting the role of dyslipidemia in the regulation of BP and the development of hypertension. 35, 36 It has been shown that fibrates reduce BP in several models of experimental hypertension such as Dahl salt-sensitive rats, spontaneously hypertensive rats and fructose-induced hypertensive rats. [9] [10] [11] There are also several clinical studies that showed significant reductions in BP with fibrates in patients with hypertriglyceridemia, 12 hypertension and hypertriglyceridemia 13 and metabolic syndrome. 37 Several mechanisms for the reduction in BP with fibrates have been considered, including improved insulin sensitivity, increased renal blood flow and reduced renal vascular resistance, and improved endothelium-dependent nitric oxide-mediated vasodilatation. [9] [10] [11] [12] [13] 38 However, the results of clinical studies examining the effect of fibrates on BP have been inconsistent. In some studies, clofibrate or fenofibrate did not lower BP in patients with type 2 diabetes mellitus. 14, 39 In the present study, bezafibrate did not affect any of the office, home or 24-h BP levels in hypertensive patients with dyslipidemia. To our knowledge, the effects of fibrates on home BP have not been investigated, and there is only one study that examined the effect of bezafibrate on 24-h ambulatory BP. 15 Home and ambulatory BP are considered to have clinical values greater than that of clinic BP. It has been shown that these BP measures correlated more closely with hypertensive target organ damage and cardiovascular prognosis than clinic BP. 16, 17, 40, 41 Home BP and ambulatory BP are not influenced by the placebo effect or observer bias, and can detect small changes in BP caused by pharmacological and non-pharmacological interventions in a limited number of subjects. [18] [19] [20] Therefore, our study does not support the concept that fibrates exert a clinically relevant antihypertensive effect on hypertensive patients with dyslipidemia. Earlier studies that showed reductions in BP with fibrates used only casual BP measurements, and the two studies 13, 37 were not controlled. In the study using ambulatory BP monitoring, fenofibrate somewhat elevated 24-h systolic BP in healthy subjects and did not affect the glucocorticoid-induced BP elevation. 15 Hyperinsulinemia is thought to elevate BP through sodium retention, activation of the sympathetic nervous system, endothelial dysfunction and vascular remodeling. 2, 4 However, insulin also has vasodilatory properties and its effects on BP may be complex. In the present study, bezafibrate significantly reduced serum insulin and improved insulin sensitivity, but did not affect BP in hypertensive patients with dyslipidemia, although average baseline levels of insulin and HOMA were not elevated. These results are in accordance with our previous study in which BP in overweight subjects was reduced by weight reduction with a hypocaloric diet, but not by treatment with the insulin-sensitizing agent troglitazone. 20 Our study may have several limitations. First, we did not insert a washout period between the control and bezafibrate periods. However, the effect of treatment was likely to disappear after 2 months because levels of serum lipids, glucose and insulin were significantly different between the two periods. Second, our study was not double-blinded and was carried out without administration of a placebo in the control period. However, the present study was undertaken in a randomized crossover manner, and we used home and ambulatory BP measurements, which can avoid the placebo effect and observer bias. These methods are considered to minimize the weakness of the study design. Third, the number of study subjects was not large, although earlier studies showing positive effect of fibrates on BP 12,13 employed even fewer subjects than our study. Finally, the majority of the study subjects were treated with antihypertensive drugs, and the levels of BP, lipids, glucose and insulin were not very high. It is possible that bezafibrate exerts an antihypertensive effect if these levels are remarkably elevated in study subjects. However, in the present study average office BP in the control period was about 150/ 90 mm Hg, which appears to be high enough to investigate the effect of intervention on BP.
In conclusion, treatment with bezafibrate significantly improved the serum lipid profile and insulin sensitivity, but did not affect 
